

# Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction

## Learning Objectives

*After completing this activity, the participant should be better able to:*

- Explain the mechanisms of action of checkpoint inhibitors and their impact on novel therapies in cancer
- Identify current strategies in immunotherapy combination with molecular therapies in cancer
- Evaluate and implement immunotherapy options for malignant melanoma
- Identify current strategies in treatment of non-small-cell lung cancer utilizing immune checkpoint pathway inhibitors
- Identify currently accruing immunotherapy options for head & neck cancer
- Identify patterns of response with emerging immunotherapy options for hematological malignancies
- Describe the emerging immunotherapeutic approaches for renal cell carcinoma
- Describe emerging immunotherapeutic approaches for bladder cancer
- Identify currently accruing immunotherapy options for prostate cancer
- Select immunotherapy options for hepatic and gastrointestinal cancers
- Identify the role of neoantigens in the immunotherapy options for ovarian cancer
- Increase the awareness of currently accruing immunotherapy modality combination clinical trials across tumor types
- Differentiate the safety profile between conventional and immunotherapy treatment option for cancer
- Describe the role of prognostic and predictive biomarkers in the immunotherapeutic approaches
- Evaluate the unique toxicity issues with immunotherapy options across tumor types

## CANCERNET

